Such new approaches need to be fitted to specific CKD-related disturbances in the Nrf2 system, such as increases in GSK-3β, CKD-related protein modifications on Nrf2 and Nrf2 target proteins, and accumulation of uremic toxins. Here, GSK3B is linked to chronic kidney disease.